U.S. Markets closed

Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapies, decitabine and venetoclax.

  • The safety run-in comprised six evaluable patients.

  • In the preliminary safety data review, five patients responded to treatment, including four achieving complete response (CR) and one complete response with incomplete hematologic recovery (CRi).

  • CR rates to combination treatment with decitabine and venetoclax for relapsed/refractory AML patients is 42-52% and 0-39% for relapsed/refractory secondary AML patients.

  • Response rates to frontline treatment decitabine and venetoclax for newly diagnosed AML patients are 62-71%.

  • Interim data showed the treatment was well-tolerated, and no dose-limiting toxicities were observed.

  • Three patients remained on treatment for more than one cycle.

  • The Phase 2 clinical trial continues with 21 patients currently enrolled across all three cohorts.

  • Price Action: BPTH shares are up 19.5% at $8.4 in the premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.